A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease

Keerthanaa Balasubramanian Shanthi, Sreeram Krishnan, P Rani, Keerthanaa Balasubramanian Shanthi, Sreeram Krishnan, P Rani

Abstract

Objective: Amyloid 1-42 (Aβ42) and tau in cerebrospinal fluid are currently used as markers for diagnosis of Alzheimer's disease. Conflicting reports exist regarding their plasma levels in Alzheimer's disease patients. A meta-analysis was performed to statistically validate the use of plasma Aβ42 and tau as biomarkers for Alzheimer's disease.

Methods: Different databases were searched using the search key: (amyloid OR amyloid1-42 OR Aβ42) AND (tau OR total tau) AND plasma AND (alzheimer's OR alzheimer's disease), and for databases not accepting boolean search, records were retrieved using the search key: plasma + amyloid + tau + alzheimer's. A total of 1880 articles for Aβ42 and 1508 articles for tau were shortlisted. The abstracts were screened, and 69 articles reporting plasma Aβ42 levels and 6 articles reporting plasma tau were identified. After exclusion, 25 studies reporting plasma Aβ42 and 6 studies reporting total tau were analysed in Review Manager version 5.2 using weighted mean difference method, and the bias between studies was assessed using the funnel plot.

Results: Plasma Aβ42 and tau did not vary significantly between Alzheimer's disease patients and controls. The funnel plot showed that there was no bias between studies for Aβ42, while possible bias existed for tau due to availability of limited studies.

Conclusion: This analysis pinpoints that plasma Aβ42 and tau could not serve as reliable markers independently for diagnosis of Alzheimer's disease and a cohort study with age, sex and apolipoprotein E correction is warranted for their possible use as Alzheimer's disease markers.

Keywords: Alzheimer’s disease; Meta-analysis; Review Manager; plasma Aβ42; plasma tau; tau-to-amyloid ratio.

Conflict of interest statement

Declaration of conflicting interests: The authors declare no conflict of interest in preparing this article.

Figures

Figure 1.
Figure 1.
Data retrieval process for meta-analysis of (a) plasma Aβ42 and (b) total tau as markers for AD diagnosis.
Figure 2.
Figure 2.
Forest plots for (a) plasma Aβ42 and (b) total tau in AD patients compared to controls. The figure indicates the mean and SD (pg/mL) along the weighted mean difference and 95% confidence interval of each study included in the meta-analysis.
Figure 3.
Figure 3.
Funnel plots of (a) plasma Aβ42 and (b) total tau in AD patients.

References

    1. Roher AE, Esh CL, Kokjohn TA, et al. Aβ peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement 2009; 5(1): 18–29.
    1. Pesini P, Perez-Grijalba V, Monle I, et al. Reliable measurements of the β-amyloid pool in blood could help in the early diagnosis of AD. Int J Alzheimer Dis 2012; 2012: 604141 (10 pp.).
    1. Agarwal R, Chhillar N, Mishra VN, et al. CSF tau and amyloid β42 levels in Alzheimer’s disease – a meta-analysis. Adv Alzheimer Dis 2012; 1: 30–44.
    1. Buerger K, Frisoni G, Uspenskaya O, et al. Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 2009; 44(9): 579–585.
    1. Diniz BSO, Pinto JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 2008; 9(3): 172–182.
    1. Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64(3): 343–349.
    1. Kapaki E, Paraskevas GP, Zalonis I, et al. CSF tau protein and β-amyloid (1-42) in Alzheimer’s disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol 2003; 10(2): 119–128.
    1. Cosentino S, Stern Y, Sokolov E, et al. Plasma Amyloid β predicts cognitive decline. Arch Neurol 2010; 67(12): 1485–1490.
    1. Song F, Poljak A, Valenzuela M, et al. Meta-analysis of plasma amyloid-β levels in Alzheimer’s disease. J Alzheimers Dis 2011; 26(2): 365–375.
    1. Krishnan S, Rani P. Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer’s disease. Biol Trace Elem Res 2014; 158(2): 158–165.
    1. Sparks DL, Kryscio RJ, Sabbagh MN, et al. Tau is reduced in AD plasma and validation of employed ELISA methods. Am J Neurodegener Dis 2012; 1(1): 99–106.
    1. Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther 2013; 5(2): 9–11.
    1. Moher D, Liberati A, Tetzlaff J, et al. The PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
    1. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Meth 2005; 5: 13.
    1. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer’s disease. J Neurol 1996; 141(1–2): 65–68.
    1. Kosaka T, Imagawa M, Seki K, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 1997; 48(3): 741–745.
    1. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer’s disease. Ann Neurol 1999; 46(3): 412–416.
    1. Mehta PD, Pirttila T, Patrick BA, et al. Amyloid b protein 1 ± 40 and 1 ± 42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001; 304: 102–106.
    1. Arvanitakis Z, Lucas JA, Younkin LH, et al. Serum creatinine levels correlate with plasma amyloid Beta protein. Alzheimer Dis Assoc Disord 2002; 16(3): 187–190.
    1. Fukumoto H, Tennis M, Locascio JJ, et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003; 60(7): 958–964.
    1. Sobów T, Flirski M, Koszewska I, et al. Plasma levels of A β peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer’s disease. Acta Neurobiol Exp 2005; 65: 117–124.
    1. Pesaresi M, Lovati C, Bertora P, et al. Plasma levels of beta-amyloid (1-42) in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 2006; 27(6): 904–905.
    1. Kulstad JJ, Green PS, Cook DG, et al. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 2006; 66(10): 1506–1510.
    1. Abdullah L, Paris D, Luis C, et al. The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels. Neurosci Lett 2007; 428(2–3): 53–58.
    1. Giedraitis V, Sundelöf J, Irizarry MC, et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer’s disease. Neurosci Lett 2007; 427(3): 127–131.
    1. Sedaghat F, Dedousi E, Costa V, et al. Plasma levels of amyloid beta1-42 are independent of neuronal function in Alzheimer’s disease. J Alzheimers Dis 2009; 17(2): 343–348.
    1. Bastard NL, Aerts L, Leurs J, et al. No correlation between time-linked plasma and CSF Ab levels. Neurochem Int 2009; 55: 820–825.
    1. Zhou L, Chan KH, Chu LW, et al. Plasma amyloid-beta oligomers level is a biomarker for Alzheimer’s disease diagnosis. Biochem Biophys Res Commun 2012; 423(4): 697–702.
    1. Uslu S, Akarkarasu ZE, Ozbabalik D, et al. Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer’s disease and vascular dementia. Neurochem Res 2012; 37(7): 1554–1559.
    1. Rembach A, Faux NG, Watt AD, et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease. Alzheimers Dement 2014; 10(1): 53–61.
    1. Wang T, Xiao S, Liu Y, et al. The efficacy of plasma biomarkers in early diagnosis of Alzheimer’s disease. Int J Geriatr Psychiatry 2014; 29: 713–719.
    1. Swaminathan S, Risacher SL, Yoder KK, et al. Association of plasma and cortical beta-amyloid is modulated by APOE ε4 status. Alzheimers Dement 2014; 10(1): e9–e18.
    1. Tzen KY, Yang SY, Chen TF, et al. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer’s disease. ACS Chem Neurosci 2014; 5(9): 830–836.
    1. Chiu M, Chen Y, Chen T, et al. Plasma tau as a window to the brain – negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer’s disease. Hum Brain Mapp 2014; 35(7): 3132–3142.
    1. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001; 81(2): 741–766.
    1. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994; 13(1): 45–53.
    1. Kawarabayashi T, Younkin LH, Saido TC, et al. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci 2001; 21(2): 372–381.
    1. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64(3): 354–362.
    1. Okereke OI, Xia W, Selkoe DJ, et al. Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 2009; 66(10): 1247–1253.
    1. Van Oijen M, Hofman A, Soares HD, et al. Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006; 5(8): 655–660.
    1. Deane R, Sagare A, Hamm K, et al. apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest 2008; 118(12): 4002–4013.
    1. Fryer JD, Simmons K, Parsadanian M, et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 2005; 25(11): 2803–2810.
    1. Kuo YM, Kokjohn TA, Watson MD, et al. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol 2000; 156(3): 797–805.
    1. Li QX, Whyte S, Tanner JE, et al. Secretion of Alzheimer’s disease Abeta amyloid peptide by activated human platelets. Lab Invest 1998; 78(4): 461–469.
    1. Van Nostrand WE, Melchor JP. Disruption of pathologic amyloid beta-protein fibril assembly on the surface of cultured human cerebrovascular smooth muscle cells. Amyloid 2001; 8(Suppl. 1): 20–27.
    1. Deane R, Bell RD, Sagare A, et al. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 2009; 8(1): 16–30.
    1. Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004; 43(3): 333–344.
    1. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol 2006; 112(4): 405–415.
    1. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 1996; 382(6593): 685–691.
    1. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J 2004; 18(7): 902–904.
    1. Park SJ, Kleffmann T, Hessian PA. The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant. J Biol Chem 2011; 286(24): 21384–21392.
    1. Tamaki C, Ohtsuki S, Iwatsubo T, et al. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 2006; 23(7): 1407–1416.
    1. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58(3): 373–379.
    1. Buerger K, Zinkowski R, Teipel SJ, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59(8): 1267–1272.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel